国家药品监督管理局官网显示,康方生物全球首创双特异性抗体新药依沃西新适应症获批上市,单药用于PD-L1表达阳性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗。依沃西的数据是今年医药行业最受关注的数据之一。康方生物称,依沃西一线治疗PD-L1阳性NSCLC新适应症的获批上市,是基于依沃西“头对头”默沙东帕博利珠单抗(K药)的随机、双盲、对照III期临床研究HARMONi-2中获得的显著的阳性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.